Gene therapy for spinal cord disorders
US10744210B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Nov 2, 2007 |
| Grant date | Aug 18, 2020 |
| Priority date | — |
| Expiry date | Nov 22, 2027 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2799/025
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This disclosure provides methods and compositions for treating disorders or injuries that affect motor function and control in a subject. In one aspect, the invention provides a method to deliver a transgene to a subject's spinal cord by administering a recombinant neurotropic viral vector containing the transgene. The viral vector delivers the transgene to a region of the deep cerebellar nuclei region of the brain. Also provided are compositions and methods to deliver a transgene to a subject's spinal cord by administering a recombinant neurotropic viral vector containing the transgene to the motor cortex region of the subject's brain.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.